Inicio › Cáncer de endometrio › Oregón
Ensayos clínicos de Cáncer de endometrio en Oregón
27 estudios sobre Cáncer de endometrio buscan participantes en Oregón.
Ciudades en Oregón
Texto oficial del estudio (inglés)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT05112601Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- y 3 más
ReclutandoFase 2
Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 10 nov 2026 · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Providence Cancer Institute of Oregon, Portland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06515613Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 6 nov 2026 · NCT07198074cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05366881Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- NW Cancer Specs. P.C., Happy Valley
- USOR - NW Cancer Specs P.C., Portland
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 3 nov 2026 · NCT07166094Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Northwest Cancer Specialists, P.C., Happy Valley
- Northwest Cancer Specialists, P.C., Portland
- Northwest Cancer Specialists, P.C., Tigard
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 30 oct 2026 · NCT07578649A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06242470A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT04657068Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
- Providence Cancer Institute (Westside), Portland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06293898DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Eugene
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 13 oct 2026 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Oregon Health and Science University, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 oct 2026 · NCT05919264Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
ReclutandoFase 1/2
Edades de 18 a 130 · Todos los sexos · Actualizado el 5 oct 2026 · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07814248Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05867251Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Eugene
- Research Site, Portland
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 29 jul 2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jul 2026 · NCT06974110Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 16 jul 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 jul 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Oncology Associates of Oregon, P.C., Eugene
- Northwest Cancer Specialists, P.C., Portland
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 24 dic 2025 · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Oregon Health & Science University, Portland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2025 · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oncology Associates of Oregon, Eugene
- Northwest Cancer Specialists, Portland
ReclutandoFase 2/3
Edades de 18 en adelante · Mujeres · Actualizado el 2 may 2024 · NCT05797831De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.